Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.


BACKGROUND Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs. At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs. Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols. Therefore, we… (More)


4 Figures and Tables